Cefiderocol + Ampicillin-sulbactam + Colistin + Meropenem
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carbapenem Resistant Bacterial Infection
Conditions
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
Trial Timeline
Sep 1, 2024 → Sep 1, 2026
NCT ID
NCT05922124About Cefiderocol + Ampicillin-sulbactam + Colistin + Meropenem
Cefiderocol + Ampicillin-sulbactam + Colistin + Meropenem is a approved stage product being developed by Johnson & Johnson for Carbapenem Resistant Bacterial Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05922124. Target conditions include Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05922124 | Approved | Recruiting |
Competing Products
1 competing product in Carbapenem Resistant Bacterial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imipenem+Relebactam | Merck | Approved | 85 |